DE69920247D1 - Veränderung der dns methyltransferase durch kombinationstherapie - Google Patents

Veränderung der dns methyltransferase durch kombinationstherapie

Info

Publication number
DE69920247D1
DE69920247D1 DE69920247T DE69920247T DE69920247D1 DE 69920247 D1 DE69920247 D1 DE 69920247D1 DE 69920247 T DE69920247 T DE 69920247T DE 69920247 T DE69920247 T DE 69920247T DE 69920247 D1 DE69920247 D1 DE 69920247D1
Authority
DE
Germany
Prior art keywords
change
combination therapy
methyl transferase
dna methyl
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69920247T
Other languages
English (en)
Other versions
DE69920247T2 (de
Inventor
M Besterman
Robert Macleod
M Siders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methylgene Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Application granted granted Critical
Publication of DE69920247D1 publication Critical patent/DE69920247D1/de
Publication of DE69920247T2 publication Critical patent/DE69920247T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01045—Thymidylate synthase (2.1.1.45)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69920247T 1998-10-19 1999-10-19 Veränderung der dns methyltransferase durch kombinationstherapie Expired - Fee Related DE69920247T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10480498P 1998-10-19 1998-10-19
US104804P 1998-10-19
PCT/US1999/024278 WO2000023112A1 (en) 1998-10-19 1999-10-19 Modulation of gene expression by combination therapy

Publications (2)

Publication Number Publication Date
DE69920247D1 true DE69920247D1 (de) 2004-10-21
DE69920247T2 DE69920247T2 (de) 2005-09-29

Family

ID=22302488

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920247T Expired - Fee Related DE69920247T2 (de) 1998-10-19 1999-10-19 Veränderung der dns methyltransferase durch kombinationstherapie

Country Status (8)

Country Link
EP (1) EP1123111B1 (de)
JP (1) JP2002528391A (de)
AT (1) ATE275956T1 (de)
AU (1) AU766084B2 (de)
CA (1) CA2347003A1 (de)
DE (1) DE69920247T2 (de)
ES (1) ES2228119T3 (de)
WO (1) WO2000023112A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071703A2 (en) * 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
EP2093292A2 (de) * 2000-03-24 2009-08-26 Methylgene, Inc. Spezifische Hemmung von Histon-deacylasen Isoformen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002069947A2 (en) * 2001-01-12 2002-09-12 Methylgene, Inc. Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20030083292A1 (en) * 2001-05-11 2003-05-01 Macleod Alan Robert Inhibitors of DNA methyltransferase isoforms
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2002340253C1 (en) 2001-10-16 2011-03-31 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
DE60229890D1 (de) 2002-09-30 2008-12-24 Hoffmann La Roche Oligonukleotide zur genotypisierung des thymidylat-synthase gens
CA2503027A1 (en) * 2002-10-21 2004-05-06 University Of Medicine And Dentistry Of New Jersey Thymidylate synthase polymorphisms for use in screening for cancer susceptibility
JP4543188B2 (ja) * 2004-03-10 2010-09-15 学校法人日本医科大学 ヒトチミジル酸合成酵素に対するＲＮＡｉとして作用するＲＮＡ配列
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP2198042B1 (de) 2007-09-17 2016-11-02 MDxHealth SA Neue marker zum nachweis von blasenkrebs
EP3431142B1 (de) 2011-08-30 2020-06-17 Astex Pharmaceuticals, Inc. Decitabinderivatformulierungen
US10184933B2 (en) 2013-10-01 2019-01-22 The J. David Gladstone Industries Compositions, systems and methods for gene expression noise drug screening and uses thereof
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
RU2020108580A (ru) 2017-08-03 2021-09-03 Оцука Фармасьютикал Ко., Лтд. Лекарственное соединение и способы его очистки
US20190374656A1 (en) * 2018-06-11 2019-12-12 Aether Therapeutics Inc. Methods for maintaining optimum dna methylation by endogenous methylation and demethylation of dna
US11938143B2 (en) * 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008625A1 (en) * 1992-10-21 1994-04-28 Temple University - Of The Commonwealth System Of Higher Education Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases

Also Published As

Publication number Publication date
WO2000023112A9 (en) 2000-08-31
DE69920247T2 (de) 2005-09-29
EP1123111A1 (de) 2001-08-16
JP2002528391A (ja) 2002-09-03
AU766084B2 (en) 2003-10-09
AU6519499A (en) 2000-05-08
WO2000023112A1 (en) 2000-04-27
CA2347003A1 (en) 2000-04-27
ES2228119T3 (es) 2005-04-01
ATE275956T1 (de) 2004-10-15
EP1123111B1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
DE69920247D1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
WO2002036743A3 (en) Antisense modulation of calreticulin expression
AU2001290706A1 (en) Antisense modulation of clusterin expression
EP1131465A4 (de) Antisense-modulierung der interleukin-15 expression
BR9913878A (pt) Sintases
EP1569695A4 (de) Antisense-modulationder apolipoprotein-b-expression
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
EP1189918A4 (de) Antisense-modulation der integrin-beta-3-expression
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
EP1135402A4 (de) Antisense modulation der egr-1 expression
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2004016754A3 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
EP1131332A4 (de) Antisense-modulation der inhibitor-kappa b kinase-beta expression
EP1131107A4 (de) Antisense-modulation der expression von inhibitor-kappa-b-kinase-alpha
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2003099215A3 (en) Antisense modulation of glucocorticoid receptor expression
EP1163373A4 (de) Antisense-modulation des zellulären hemmstoffs der apoptosis-expression
EP1248633A4 (de) Antisense-modulation der expression von glycogen-synthase kinase 3 beta
EP1165145A4 (de) Antisense-modulation der mdmx-expression
EP1248795A4 (de) Antisens-modulierung der expression des makrophagenmigrationshemmenden faktors
WO2003057847A8 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee